At a glance
ClinicalIndex Comparison Record- ✓Men aged 21–50 years
- ✓Meet DSM-5 criteria for current alcohol use disorder
- ✓Average weekly alcohol use of 25–70 standard drinks over the past 30 days
- ✓No more than 3 days/week of alcohol abstinence in the past 30 days
- ✕Currently seeking AUD treatment or in treatment within the past 6 months
- ✕Current DSM-5 non-alcohol use disorder other than tobacco or cannabis
- ✕Positive urine drug test for opioids, cocaine, benzodiazepines, or barbiturates at more than one baseline appointment
- ✕Regular use of psychoactive drugs (antipsychotics, anxiolytics, antidepressants, anticonvulsants, beta blockers, CNS stimulants/depressants, or excessive sedating agents) in the 30 days prior to entry
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Placebo-controlled Human Laboratory Feasibility Study of Lacosamide Effects in Alcohol Use Disorder
In Brief
A Phase 2 clinical trial evaluating Placebo, Lacosamide 100 mg, and 1 other intervention for Alcohol Use Disorder. Completed, enrolled 4 participants across 1 site.
Detailed Summary
The overall goal of the proposed project is to improve the treatment of individuals with AUD. The investigators will conduct the first pilot human laboratory study to assess the effects of two doses of lacosamide on alcohol drinking and craving. The investigators will assess its effects on reducing alcohol intake using a human laboratory method, the Yale Alcohol Drinking Paradigm (ADP). The investigators will also assess the feasibility of the Alcohol Drinking Paradigm (ADP) in order to position our research team to have the capacity to conduct future, larger, hypothesis-testing human laboratory-based experiments designed to test the efficacy of potential alcohol treatments.
Study Details
Timeline
Interventions
Oral medication
Oral medication
Oral medication